Single dose intravenous tranexamic acid as effective as continuous infusion in primary total knee arthroplasty: a randomised clinical trial

Archives of Orthopaedic and Trauma Surgery

Volumn 135, Issue 4, 2015, Pages 465-471

  Hourlier, Hervé ^a   Reina, Nicolas ^b   Fennema, Peter ^c  

^a Polyclinique de la Thiérache ^*  (France)

^b TOULOUSE UNIVERSITY HOSPITAL   (France)

^c AMR Advanced Medical Research   (Switzerland)

Author keywords

Blood transfusion; Knee osteoarthritis; Randomised clinical trial; Total knee arthroplasty; Tranexamic acid

Indexed keywords

HEMOGLOBIN; TRANEXAMIC ACID; ANTIFIBRINOLYTIC AGENT;

ADULT; AGED; ARTICLE; BLOOD TRANSFUSION; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; FEMALE; FOLLOW UP; HEMATOCRIT; HEMATOMA; HEMOGLOBIN BLOOD LEVEL; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTIPLE LINEAR REGRESSION ANALYSIS; OPERATIVE BLOOD LOSS; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; THROMBOEMBOLISM; TOTAL KNEE REPLACEMENT; DOSE RESPONSE; INTRAOPERATIVE COMPLICATIONS; INTRAVENOUS DRUG ADMINISTRATION; KNEE ARTHROPLASTY; OSTEOARTHRITIS, KNEE; PEROPERATIVE CARE; PROCEDURES; THROMBOSIS; TREATMENT OUTCOME;

AGED; ANTIFIBRINOLYTIC AGENTS; ARTHROPLASTY, REPLACEMENT, KNEE; BLOOD TRANSFUSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INTRAOPERATIVE CARE; INTRAOPERATIVE COMPLICATIONS; MALE; OSTEOARTHRITIS, KNEE; POSTOPERATIVE PERIOD; THROMBOSIS; TRANEXAMIC ACID; TREATMENT OUTCOME;

EID: 84925491230     PISSN: 09368051     EISSN: 14343916     Source Type: Journal    
DOI: 10.1007/s00402-015-2168-z     Document Type: Article

References (31)

1. Zufferey P, Merquiol F, Laporte S, Decousus H, Mismetti P, Auboyer C, Samama CM, Molliex S (2006) Do antifibrinolytics reduce allogeneic blood transfusion in orthopedic surgery? Anesthesiology 105(5):1034–1046
2. Goodnough LT (2005) Risks of blood transfusion. Anesthesiol Clin North Am 23(2):241–252
3. Spahn DR, Casutt M (2000) Eliminating blood transfusions: new aspects and perspectives. Anesthesiology 93(1):242–255
4. Goodnough LT, Shander A (2007) Blood management. Arch Pathol Lab Med 131(5):695–701
5. Mannucci PM (1998) Hemostatic drugs. N Engl J Med 339(4):245–253
6. Verstraete M (1985) Clinical application of inhibitors of fibrinolysis. Drugs 29(3):236–261
7. Dowd NP, Karski JM, Cheng DC, Carroll JA, Lin Y, James RL, Butterworth J (2002) Pharmacokinetics of tranexamic acid during cardiopulmonary bypass. Anesthesiology 97(2):390–399
8. Crash-2 trial collaborators, Shakur H, Roberts I, Bautista R, Caballero J, Coats T, Dewan Y, Dewan Y, El-Sayed H, Gogichaishvili T, Gupta S, Herrera J, Hunt B, Iribhogbe P, Izurieta M, Khamis H, Komolafe E, Marrero MA, Mejia-Mantilla J, Miranda J, Morales C, Olaomi O, Olldashi F, Perel P, Peto R, Ramana PV, Ravi RR, Yutthakasemsunt S (2010) Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet 376(9734):23–32
9. Henry DA, Carless PA, Moxey AJ, O’Connell D, Stokes BJ, Fergusson DA, Ker K (2011) Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 3:CD001886
10. Hiippala S, Strid L, Wennerstrand M, Arvela V, Mantyla S, Ylinen J, Niemela H (1995) Tranexamic acid (Cyklokapron) reduces perioperative blood loss associated with total knee arthroplasty. Br J Anaesth 74(5):534–537
11. Gillette BP, DeSimone LJ, Trousdale RT, Pagnano MW, Sierra RJ (2013) Low risk of thromboembolic complications with tranexamic acid after primary total hip and knee arthroplasty. Clin Orthop Relat Res 471(1):150–154
12. CBO (2011) Blood saving techniques and medications. Blood transfusion guideline. CBO, Utrecht, pp 321–384
13. Kim TK, Chang CB, Koh IJ (2014) Practical issues for the use of tranexamic acid in total knee arthroplasty: a systematic review. Knee Surg Sports Traumatol Arthrosc 22(8):1849–1858
14. Fu DJ, Chen C, Guo L, Yang L (2013) Use of intravenous tranexamic acid in total knee arthroplasty: a meta-analysis of randomized controlled trials. Chin J Traumatol 16(2):67–76
15. Benoni G, Fredin H (1996) Fibrinolytic inhibition with tranexamic acid reduces blood loss and blood transfusion after knee arthroplasty: a prospective, randomised, double-blind study of 86 patients. J Bone Joint Surg Br 78(3):434–440
16. Ralley FE, Berta D, Binns V, Howard J, Naudie DD (2010) One intraoperative dose of tranexamic acid for patients having primary hip or knee arthroplasty. Clin Orthop Relat Res 468(7):1905–1911
17. Hourlier H, Fennema P (2014) Single tranexamic acid dose to reduce perioperative morbidity in primary total hip replacement: a randomised clinical trial. Hip Int 24(1):63–68
18. Gilbody J, Dhotar HS, Perruccio AV, Davey JR (2014) Topical tranexamic acid reduces transfusion rates in total hip and knee arthroplasty. J Arthroplasty 29(4):681–684
19. Hourlier H, Fennema P, Line B (2008) A novel blood-saving plan for less-invasive primary total hip replacement. Orthopedics 31 (12 Suppl 2)
20. Gross JB (1983) Estimating allowable blood loss: corrected for dilution. Anesthesiology 58(3):277–280
21. Gilcher RO, Belcher AJ (1983) Predeposit programs. In: Sander G, Silvergleid AJ (eds) Autologous transfusion. American Association of Blood Banks, Arlington
22. McConnell JS, Shewale S, Munro NA, Shah K, Deakin AH, Kinninmonth AW (2011) Reduction of blood loss in primary hip arthroplasty with tranexamic acid or fibrin spray. Acta Orthop 82(6):660–663
23. Levy O, Martinowitz U, Oran A, Tauber C, Horoszowski H (1999) The use of fibrin tissue adhesive to reduce blood loss and the need for blood transfusion after total knee arthroplasty. A prospective, randomized, multicenter study. J Bone Joint Surg Am 81(11):1580–1588
24. Julious SA (2004) Sample sizes for clinical trials with normal data. Stat Med 23(12):1921–1986
25. Schuirmann DJ (1987) A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 15(6):657–680
26. Kleinbaum D, Kupper L, Morgenstern H (1982) Epidemiologic research: principles and quantitative methods. Lifetime Learning Publications, Michigan
27. Tryon WW, Lewis C (2008) An inferential confidence interval method of establishing statistical equivalence that corrects Tryon’s (2001) reduction factor. Psychol Methods 13(3):272–277
28. Claeys MA, Vermeersch N, Haentjens P (2007) Reduction of blood loss with tranexamic acid in primary total hip replacement surgery. Acta Chir Belg 107(4):397–401
29. Sehat KR, Evans RL, Newman JH (2004) Hidden blood loss following hip and knee arthroplasty. Correct management of blood loss should take hidden loss into account. J Bone Joint Surg Br 86(4):561–565
30. Shen HL, Li Z, Feng ML, Cao GL (2011) Analysis on hidden blood loss of total knee arthroplasty in treating knee osteoarthritis. Chin Med J (Engl) 124(11):1653–1656
31. Whiting DR, Gillette BP, Duncan C, Smith H, Pagnano MW, Sierra RJ (2014) Preliminary results suggest tranexamic acid is safe and effective in arthroplasty patients with severe comorbidities. Clin Orthop Relat Res 472(1):66–72